Authors:
Michael Felkel Institute of Tropical Medicine, University Hospital of Tübingen, Tübingen, Germany

Search for other papers by Michael Felkel in
Current site
Google Scholar
PubMed
Close
,
Robert Exner Institute of Tropical Medicine, University Hospital of Tübingen, Tübingen, Germany

Search for other papers by Robert Exner in
Current site
Google Scholar
PubMed
Close
,
Regina Schleucher Institute of Tropical Medicine, University Hospital of Tübingen, Tübingen, Germany

Search for other papers by Regina Schleucher in
Current site
Google Scholar
PubMed
Close
,
Helga Lay Institute of Medical Microbiology and Hygiene, University Hospital of Tübingen, Tübingen, Germany

Search for other papers by Helga Lay in
Current site
Google Scholar
PubMed
Close
,
Ingo B. Autenrieth Institute of Medical Microbiology and Hygiene, University Hospital of Tübingen, Tübingen, Germany

Search for other papers by Ingo B. Autenrieth in
Current site
Google Scholar
PubMed
Close
,
Volkhard A. J. Kempf Institute of Medical Microbiology and Hygiene, Johann-Wolfgang Goethe University, Frankfurt, Germany

Search for other papers by Volkhard A. J. Kempf in
Current site
Google Scholar
PubMed
Close
, and
Dr. Julia-Stefanie Frick Institute of Medical Microbiology and Hygiene, University Hospital of Tübingen, Tübingen, Germany

Search for other papers by Dr. Julia-Stefanie Frick in
Current site
Google Scholar
PubMed
Close
Restricted access

Abstract

The incidence of tuberculosis (TB) and especially multidrug-resistant TB (MDR) continues to increase alarmingly worldwide, and reliable and fast diagnosis of MDR is essential for the adequate treatment of patients. In contrast to the standard culture methods, nucleid acid amplification tests (NAATs) provide information about presence of Mycobacterium tuberculosis complex (MTBC) DNA and a potential resistance pattern within hours. We analyzed specimens of 110 patients from Nigeria comparing culture-based drug susceptibility testing (DST) to NAAT assays detecting isoniazid (INH), rifampicin (RMP) (GenoType MTBDRplus), and ethambutol (EMB) (GenoType MTBDRsl) resistance. Compared to DST, the GenoType MTBDRplus and MTBDRsl showed a specificity of 100% (86.3–100) and a sensitivity of 86% (42.1–99.6%) for detection of INH and a specificity of 100% (86.3–100) and a sensitivity of 83% (35.9–99.6%) for detection of RMP, and a sensitivity 100% (47.8–100%) for EMB resistance. However, in two strains, the NAAT assays provided false susceptible results as the mutations causing resistance were in genomic regions not covered by the probes of the GenoType MTBDRplus assay. We show that, in combination to DST, application of the GenoType MTBDRplus and GenoType MTBDRsl assays might be a useful additional tool to allow a rapid and safe diagnosis of MDR and extensively drug-resistant (XDR) MTBC.

  • 1. AE Ani J Idoko YB Dalyop SL Pitmang 2009 Drug resistance profile of Mycobacterium tuberculosis isolates from pulmonary tuberculosis patients in Jos, Nigeria Trans R Soc Trop Med Hyg 103 67 71.

    • Search Google Scholar
    • Export Citation
  • 2. AO Kehinde FA Obaseki OC Ishola KD Ibrahim 2007 Multidrug resistance to Mycobacterium tuberculosis in a tertiary hospital J Natl Med Assoc 99 1185 1189.

    • Search Google Scholar
    • Export Citation
  • 3. NR Gandhi A Moll AW Sturm R Pawinski T Govender U Lalloo K Zeller J Andrews G Friedland 2006 Extensively drug-resistant tuberculosis as a cause of death in patients coinfected with tuberculosis and HIV in a rural area of South Africa Lancet 368 1575 1580.

    • Search Google Scholar
    • Export Citation
  • 4. VS Kiet NT Lan DD An NH Dung DV Hoa CN van Vinh NT Chinh J Farrar M Caws 2010 Evaluation of the MTBDRsl test for detection of second-line-drug resistance in Mycobacterium tuberculosis J Clin Microbiol 48 2934 2939.

    • Search Google Scholar
    • Export Citation
  • 5. D Hillemann S Rusch-Gerdes E Richter 2007 Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens J Clin Microbiol 45 2635 2640.

    • Search Google Scholar
    • Export Citation
  • 6. A Telenti N Honore C Bernasconi J March A Ortega B Heym HE Takiff ST Cole 1997 Genotypic assessment of isoniazid and rifampin resistance in Mycobacterium tuberculosis: a blind study at reference laboratory level J Clin Microbiol 35 719 723.

    • Search Google Scholar
    • Export Citation
  • 7. I Mokrousov O Narvskaya T Otten E Limeschenko L Steklova B Vyshnevskiy 2002 High prevalence of KatG Ser315Thr substitution among isoniazid-resistant Mycobacterium tuberculosis clinical isolates from northwestern Russia, 1996 to 2001 Antimicrob Agents Chemother 46 1417 1424.

    • Search Google Scholar
    • Export Citation
  • 8. JM Musser V Kapur DL Williams BN Kreiswirth van SD JD van Embden 1996 Characterization of the catalase-peroxidase gene (katG) and inhA locus in isoniazid-resistant and -susceptible strains of Mycobacterium tuberculosis by automated DNA sequencing: restricted array of mutations associated with drug resistance J Infect Dis 173 196 202.

    • Search Google Scholar
    • Export Citation
  • 9. AS Piatek A Telenti MR Murray H El-Hajj WR Jacobs Jr. FR Kramer D Alland 2000 Genotypic analysis of Mycobacterium tuberculosis in two distinct populations using molecular beacons: implications for rapid susceptibility testing Antimicrob Agents Chemother 44 103 110.

    • Search Google Scholar
    • Export Citation
  • 10. CL Kelley DA Rouse SL Morris 1997 Analysis of ahpC gene mutations in isoniazid-resistant clinical isolates of Mycobacterium tuberculosis Antimicrob Agents Chemother 41 2057 2058.

    • Search Google Scholar
    • Export Citation
  • 11. S Sreevatsan X Pan Y Zhang V Deretic JM Musser 1997 Analysis of the oxyR-ahpC region in isoniazid-resistant and -susceptible Mycobacterium tuberculosis complex organisms recovered from diseased humans and animals in diverse localities Antimicrob Agents Chemother 41 600 606.

    • Search Google Scholar
    • Export Citation
  • 12. D Hillemann S Rusch-Gerdes E Richter 2009 Feasibility of the GenoType MTBDRsl assay for fluoroquinolone, amikacin-capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens J Clin Microbiol 47 1767 1772.

    • Search Google Scholar
    • Export Citation
  • 13. A Ani T Bruvik Y Okoh P Agaba O Agbaji J Idoko UR Dahle 2010 Genetic diversity of Mycobacterium tuberculosis complex in Jos, Nigeria BMC Infect Dis 10 189.

    • Search Google Scholar
    • Export Citation
  • 14. A Barrett JG Magee R Freeman 2002 An evaluation of the BD ProbeTec ET system for the direct detection of Mycobacterium tuberculosis in respiratory samples J Med Microbiol 51 895 898.

    • Search Google Scholar
    • Export Citation
  • 15. DI Ling LL Flores LW Riley M Pai 2008 Commercial nucleic-acid amplification tests for diagnosis of pulmonary tuberculosis in respiratory specimens: meta-analysis and meta-regression PLoS ONE 3 e1536.

    • Search Google Scholar
    • Export Citation
  • Collapse
  • Expand
The author instructions are available in PDF.
Please, download the file from HERE.

 

Senior editors

Editor(s)-in-Chief: Dunay, Ildiko Rita

Editor(s)-in-Chief: Heimesaat, Markus M.

Editorial Board

  • Berit Bangoura (University of Wyoming, USA)
  • Stefan Bereswill (Charité - University Medicine Berlin, Germany)
  • Dunja Bruder (University of Magdeburg, Germany)
  • Jan Buer (University of Duisburg, Germany)
  • Edit Buzas (Semmelweis University, Hungary)
  • Renato Damatta (UENF, Brazil)
  • Maria Deli (Biological Research Center, HAS, Hungary)
  • Olgica Djurković-Djaković (University of Belgrade, Serbia)
  • Jean-Dennis Docquier (University of Siena, Italy)
  • Zsuzsanna Fabry (University of Washington, USA)
  • Ralf Ignatius (Charité - University Medicine Berlin, Germany)
  • Achim Kaasch (Otto von Guericke University Magdeburg, Germany)
  • Oliver Liesenfeld (Inflammatix, USA)
  • Matyas Sandor (University of Wisconsin, USA)
  • Ulrich Steinhoff (University of Marburg, Germany)
  • Michal Toborek (University of Miami, USA)
  • Susanne A. Wolf (MDC-Berlin, Germany)

 

Dr. Dunay, Ildiko Rita
Magdeburg, Germany
E-mail: ildiko.dunay@med.ovgu.de

Indexing and Abstracting Services:

  • PubMed Central
  • Scopus
  • ESCI
  • CABI
  • CABELLS Journalytics

 

2022  
Web of Science  
Total Cites
WoS
717
Journal Impact Factor 2.2
Rank by Impact Factor

n/a

Impact Factor
without
Journal Self Cites
2.2
5 Year
Impact Factor
2.8
Journal Citation Indicator 0.66
Rank by Journal Citation Indicator

Microbiology (Q2)

Scimago  
Scimago
H-index
11
Scimago
Journal Rank
0.614
Scimago Quartile Score Microbiology (Q3)
Microbiology (medical) (Q3)
Immunology and Allergy (Q3)
Immunology (Q3)
Scopus  
Scopus
Cite Score
8.3
Scopus
CIte Score Rank
Microbiology 33/163 (80th PCTL)
Microbiology (medical) 28/124 (77th PCTL)
Immunology and Allergy 63/211 (70th PCTL)
Immunology 69/217 (68th PCTL)
Scopus
SNIP
1.221

 

2021  
Web of Science  
Total Cites
WoS
790
Journal Impact Factor not applicable
Rank by Impact Factor not applicable
Impact Factor
without
Journal Self Cites
not applicable
5 Year
Impact Factor
not applicable
Journal Citation Indicator 0,64
Rank by Journal Citation Indicator Microbiology 81/157
Scimago  
Scimago
H-index
not indexed
Scimago
Journal Rank
not indexed
Scimago Quartile Score not indexed
Scopus  
Scopus
Cite Score
not indexed
Scopus
CIte Score Rank
  not indexed
Scopus
SNIP
not indexed

2020  
CrossRef Documents 23
WoS Cites 708
Wos H-index 27
Days from submission to acceptance 219
Days from acceptance to publication 176
Acceptance Rate 70%

2019  
WoS
Cites
558
CrossRef
Documents
24
Acceptance
Rate
92%

 

European Journal of Microbiology and Immunology
Publication Model Gold Open Access
Submission Fee none
Article Processing Charge 600 EUR/article
Regional discounts on country of the funding agency World Bank Lower-middle-income economies: 50%
World Bank Low-income economies: 100%
Further Discounts Editorial Board / Advisory Board members: 50%
Corresponding authors, affiliated to an EISZ member institution subscribing to the journal package of Akadémiai Kiadó: 100%
Subscription Information Gold Open Access
Purchase per Title  

European Journal of Microbiology and Immunology
Language English
Size A4
Year of
Foundation
2011
Volumes
per Year
1
Issues
per Year
4
Founder Akadémiai Kiadó
Founder's
Address
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
Publisher Akadémiai Kiadó
Publisher's
Address
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
Responsible
Publisher
Chief Executive Officer, Akadémiai Kiadó
ISSN 2062-509X (Print)
ISSN 2062-8633 (Online)

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Jan 2024 15 3 0
Feb 2024 13 1 2
Mar 2024 32 0 0
Apr 2024 29 0 0
May 2024 13 0 0
Jun 2024 8 0 0
Jul 2024 0 0 0